Centessa Pharmaceuticals Plc (CNTA)
NASDAQ:CNTA
Want to see CNTA full AI Analyst Report?
CNTA Stock Chart & Stats
$39.66
-$0.91(-5.25%)
At close: 4:00 PM EST
$39.66
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$10.95 - $40.26
Previous CloseN/A
Volume658.98K
Average Volume (3M)2.00M
Market Cap
$6.13B
Enterprise Value$6.09B
Total Cash (Recent Filing)$276.59M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding154,728,970
10 Day Avg. Volume1,137,512
30 Day Avg. Volume1,998,217
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.44
Price to Sales (P/S)226.28
P/FCF Ratio-17.48
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.03K
Enterprise Value/Ebitda-22.90
Forecast
1Y Price Target
$42.40Price Target Upside6.91% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition ValidationLilly's acquisition validates the commercial opportunity for orexin therapies and signals access to larger development and commercialization resources to accelerate programs across multiple sleep and neurological disorders.
Commercial Partnership And IntegrationSupport from a major pharmaceutical partner is expected to expand commercial reach and simplify integration given minimal overlap between the acquirer's pipeline and the company's assets.
Contingent Milestone UpsideContingent value rights tied to regulatory milestones create additional potential cash for shareholders beyond the takeover payment if development and approval goals are met.
Bears Say
Analyst Downgrades And Valuation AlignmentMultiple analyst downgrades to Hold or Market Perform and price targets aligned with the takeover price reflect expectations that the deal constrains further stock appreciation.
Reduced Standalone UpsideThe definitive acquisition agreement significantly limits independent upside for existing shareholders by lowering the likelihood of a higher competing bid.
Uncertainty Of Milestone PaymentsPayments from contingent value rights are conditional on regulatory approvals, introducing substantial uncertainty about whether the promised additional cash will materialize.
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was $10.95 and its highest was $40.26 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is $6.13B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is Aug 17, 2026 which is in 89 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Centessa Pharmaceuticals Plc released its earnings results on May 05, 2026. The company reported -$0.515 earnings per share for the quarter, missing the consensus estimate of -$0.405 by -$0.11.
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc does not currently pay dividends.
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 154,728,970 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Centessa Pharmaceuticals Plc reported an EPS of -$0.515 in its last earnings report, missing expectations of -$0.405. Following the earnings report the stock price went down -0.076%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in CNTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Centessa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.40 (6.91% Upside)
$42.40 (6.91% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
223.81%
12-Months-Change
Fundamentals
Return on Equity
-60.37%
Trailing 12-Months
Asset Growth
21.58%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
CNTA Stock 12 Month Forecast
Average Price Target
$42.40
▲(6.91% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
1.00% Insiders
11.44% Mutual Funds
76.85% Other Institutional Investors
10.10% Public Companies and
Individual Investors